In case you missed it, here are some of Benzinga's top stories from Wednesday, Jan. 24, 2018.
A Pharma Trade From Goldman
Jayson Derrick outlines a bull and bear call on Catelent, Inc CTLT and Valeant Pharmaceuticals International, Inc VRX, respectively, from Goldman Sachs. Check out “Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant.”
Puma Biotech Declawed By European Medicines Agency
Puma Biotechnology, Inc PBYI shares were crushed Wednesday after reporting a negative trend vote from European regulators regarding its neratinib compound. Learn more in Shanthi Rexaline’s “What You Need to Know About Puma Biotech's 25% Slide.”
'3 Micro-Cap Tech Stocks To Watch In 2018'
Bill Haddad checked out the LD Micro Virtual CES Wrap Up so that you don’t have to. From Vuzix Corporation VUZI to My Size, Inc MYSZ, learn why these names are worth keeping an eye on this year.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.